Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Relapsed/Refractory Lymphoma
NCT00436618Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in non-Hodgkin lymphoma (NHL), Indolent Non-Hodgkin Lymphoma (INHL), Hodgkin lymphoma (HL), T-cell lymphoma, chronic lymphocytic leukemia (CLL), sponsored by Mayo Clinic. Started Aug 2005; status: completed.
02
Drugs
everolimus
03
Conditions
non-Hodgkin lymphoma (NHL)Indolent Non-Hodgkin Lymphoma (INHL)Hodgkin lymphoma (HL)T-cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00436618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436618.